The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat individuals with mild cognitive impairment or mild dementia consistent with early ...

Bristol Myers Squibb (NYSE:BMY) believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue.

Kathy Ingebrand started to notice something was off when she found herself being short with her family. She was becoming ...

The findings suggest that specific medications may play a crucial role in preventing dementia. A study conducted by ...

According to a study published in Nature Medicine, about 42% of people over the age of 55 will develop dementia in their ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

Despite initial slow sales, the firm's CEO cited areas for Leqembi's growth and ambitions for an antisense oligonucleotide ...

After five novels about neurological conditions, the Still Alice author pens an empathetic portrayal of life with mental ...

The Florey Dementia Index (FDI) is valid for predicting the age of onset of mild cognitive impairment (MCI) and Alzheimer ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

“Even in individuals who had not yet developed kidney disease, we could see that kidney function was linked to brain atrophy.